Previous reports have shown that polymorphisms of COMT played a role in the risk of esophageal cancer [57,59], lung cancer [58], breast cancer [60,61,62], prostate cancer [63], and bladder cancer [59,64]. This evidence concerns the gene COMT and lung carcinoma.